On December 19, 2023 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO-GU) being held in San Francisco, CA and virtually on January 25-27, 2024 (Press release, Harpoon Therapeutics, DEC 19, 2023, View Source [SID1234638691]). HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to kill tumor cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the ASCO (Free ASCO Whitepaper)-GU presentation are as follows:
Title: "Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting T-Cell Engager in Patients with Neuroendocrine Prostate Cancer (NEPC) and other Neuroendocrine Neoplasms (NEN)"
Abstract number: 121
Session: Rapid Oral Abstract Session A: Prostate Cancer
Session track: Prostate Cancer – Advanced | Prostate Cancer – Localized
Session date & time: Thursday, January 25, 2024 at 4:15 PM – 5:00 PM PST
Presenter: Himisha Beltran, M.D. | Dana-Farber Cancer Institute
Location: Level 3, Ballroom | Livestream
The presentation will also be available on Harpoon’s website under Publications following the session.
For more details about the ASCO (Free ASCO Whitepaper)-GU Annual Meeting, please visit: View Source
About HPN328
HPN328 targets delta-like canonical Notch ligand 3 (DLL3) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to kill tumor cells. HPN328 is being evaluated as monotherapy in an ongoing open-label, multicenter, two-part study to assess the safety, tolerability, and pharmacokinetics in patients with advanced cancers associated with the expression of DLL3.
In March 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to HPN328 for the treatment of SCLC.